Loading
Muscle is an immune organ as well as a movement organ. Building it during immunotherapy might improve how well the treatment works, not just how patients feel.
Muscle secretes myokines including interleukin-15 and irisin that affect immune cell function, and low muscle mass is associated with poorer checkpoint inhibitor outcomes in several retrospective series. Whether that association is causal or simply reflects disease burden is unknown, and a randomised exercise and protein intervention during checkpoint therapy would answer it while also improving function.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Non-small-cell lung cancer.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Non-small-cell lung cancer.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Non-small-cell lung cancer.
Shares Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma, Immune checkpoint inhibitors.
Shares Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
Shares Definition and classification of cancer cachexia: an international consensus, Structured exercise prescribed like a drug in all curative-intent cancer care, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.